skinny.

Latest / Lymphoma Hub

Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial

During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The discussion was preceded by a presentation by Gareth Gregory, chaired by Gilles Salles, and featured Ulrich Jäger, Francesc Bosch, Michael Dickinson, Astrid Pavlovsky, Marek Trněný, Alison Moskowitz, and Stefano Luminari.

Gregory presented an overview of the STARGLO…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.